PAO-LING TORNGChan W.-YCHIN-TARNG LINHuang S.-C.2020-02-192020-02-1920030022-4790https://scholars.lib.ntu.edu.tw/handle/123456789/460906Background and Objectives: Human papillomavirus (HPV) is thought to be one of the possible causative factors in cervical carcinogenesis, and cervical carcinoma cells are refractory to tumor transforming growth factor (TGF)-β1. The purpose of this study is to investigate the possible cause-effect association between HPV and TGF-β1 during cervical tumorigenesis. Methods: We assessed the expression of HPV capsid proteins, HPV-16 E7, HPV-16 E2 (C and N terminals), TGF-β1, and their receptors TGF-β1 RI and RII by immunohistochemistry in 48 paraffin-embedded blocks of tumor tissue derived from patients of cervical neoplasia. Results: Expression of TGF-β1 decreased as tumor cells progressed from cervical intraepithelial neoplasia (CIN)1, CIN2, CIN3, to microinvasive carcinoma (P < 0.05). Levels of TGF-βRI and TGFβ-RII stayed the same in all cases. HPV was found in 89.6% of the studied sections, and cervical lesions without HPV infection expressed significantly less TGF-β1 (P < 0.05). By comparing the expression pattern of TGF-β1 and HPV in the neoplastic cells with that of normal cervical epithelium in each section, we found loss of HPV-16 E2 higher in CIN3 (15/24) than in CIN1 or CIN2 (3/7), and there is a significant trend that loss of HPV-16 E2 expression correlated with a >50% loss of TGF-β1 at the lesion site (P < 0.05). Conclusions: Our result showed co-suppression of HPV and TGF-β1 expression during progression of cervical squamous cell cancer. Using antibody against HPV-16 E2 may be an auxiliary tool for the investigation of cervical tumor progression. ? 2003 Wiley-Liss, Inc.[SDGs]SDG3transforming growth factor beta receptor; transforming growth factor beta1; unclassified drug; virus e2 protein; virus protein; article; cancer tissue; carcinogenesis; clinical article; disease marker; female; human; human tissue; immunohistochemistry; immunoreactivity; priority journal; protein expression; squamous cell carcinoma; tumor cell; uterine cervix cancer; uterine cervix carcinoma in situ; uterine cervix epithelium; Wart virus; Carcinoma, Squamous Cell; Cervical Intraepithelial Neoplasia; DNA-Binding Proteins; Female; Humans; Oncogene Proteins, Viral; Papillomaviridae; Papillomavirus Infections; Receptors, Transforming Growth Factor beta; Transforming Growth Factor beta; Transforming Growth Factor beta1; Tumor Markers, Biological; Tumor Virus Infections; Uterine Cervical Neoplasms10.1002/jso.10273129499862-s2.0-0043194050